Researchers at UW Medicine have launched a new clinical trial to test whether a GLP-1 drug can help people with alcohol use disorder reduce their drinking. The study will examine if medications like semaglutide, currently approved for type 2 diabetes and weight management, can also curb cravings for alcohol. This trial adds to a growing body of research exploring GLP-1 drugs for addiction treatment.

Key takeaways

  • UW Medicine is conducting a clinical trial to test a GLP-1 drug for alcohol use disorder.
  • The drug, similar to semaglutide, may reduce alcohol cravings by acting on brain reward pathways.
  • Early animal and human studies suggest GLP-1 medications can lower alcohol consumption.
  • If successful, this could offer a new treatment option for millions of Americans with alcohol use disorder.

What is the clinical trial studying?

The trial, led by researchers at UW Medicine, will enroll adults with moderate to severe alcohol use disorder. Participants will receive either a GLP-1 drug or a placebo for several weeks. The researchers will monitor changes in drinking patterns, cravings, and brain activity using functional MRI scans. The goal is to see if the drug reduces the number of heavy drinking days and overall alcohol intake.

According to the UW Medicine newsroom, the study builds on preclinical work showing that GLP-1 drugs can decrease alcohol seeking behavior in animals. A small human study also found that people taking these medications for diabetes reported drinking less alcohol. The new trial aims to confirm these findings in a larger, controlled setting.

How might GLP-1 drugs affect alcohol cravings?

GLP-1 drugs work by mimicking a hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. These medications also act on receptors in the brain that are involved in reward and pleasure. Researchers believe this mechanism may reduce the rewarding effects of alcohol, making it less appealing to drink.

Dr. Andrew Saxon, a psychiatrist and addiction specialist at UW Medicine, explained in the original report that the drug may dampen the brain’s response to alcohol cues. This could help people with alcohol use disorder resist the urge to drink, especially in social situations or times of stress. The trial will use brain scans to see if the drug actually changes how the brain reacts to alcohol related triggers.

Why is this research important?

Alcohol use disorder affects about 29 million adults in the United States, according to the National Institute on Alcohol Abuse and Alcoholism. Current treatment options include counseling, support groups, and a few approved medications like naltrexone and acamprosate. However, many people do not respond well to these treatments, and relapse rates remain high.

If GLP-1 drugs prove effective for alcohol use disorder, they could offer a new, well tolerated option. These medications are already widely prescribed for diabetes and obesity, so doctors are familiar with their safety profile. The UW Medicine trial could pave the way for a new use of an existing drug, potentially helping millions of people who struggle with alcohol addiction.

Frequently Asked Questions

What is a GLP-1 drug?

GLP-1 drugs, such as semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda), are medications that mimic a natural hormone involved in blood sugar control and appetite regulation. They are primarily used to treat type 2 diabetes and obesity but are now being studied for other conditions like addiction.

How can a diabetes drug help with alcohol addiction?

Researchers believe GLP-1 drugs reduce the rewarding effects of alcohol by acting on brain regions involved in pleasure and addiction. Early studies in animals and humans suggest these medications can lower alcohol cravings and consumption, possibly by making drinking less satisfying.

When will results from this trial be available?

The UW Medicine trial is currently enrolling participants, and results are not expected for at least a year. The study will need to complete data collection and analysis before any conclusions can be drawn. Researchers hope to publish their findings in a peer reviewed medical journal.

For more information on this study, visit the UW Medicine newsroom.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.